Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MAP2K1 P124Q

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L (1)

CD34 positive + BMI1 overexpression + MAP2K1 elevation (1)

MAP2K1 mutation + BRAF wild-type (1)

MAP2K1 mutation + RAS wild-type (1)

MAP2K1 mutation + TMB-H (1)

ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L (1)

CD34 positive + BMI1 overexpression + MAP2K1 elevation (1)

MAP2K1 mutation + BRAF wild-type (1)

MAP2K1 mutation + RAS wild-type (1)

MAP2K1 mutation + TMB-H (1)

›

MAP2K1 P124Q	Melanoma	MAP2K1 P124Q	Melanoma	trametinib Resistant: C3 – Early Trials trametinib Resistant : C3	trametinib Resistant: C3 – Early Trials trametinib Resistant : C3
MAP2K1 P124Q	Melanoma	MAP2K1 P124Q	Melanoma	dabrafenib Sensitive: C3 – Early Trials dabrafenib Sensitive : C3	dabrafenib Sensitive: C3 – Early Trials dabrafenib Sensitive : C3
MAP2K1 P124Q	Melanoma	MAP2K1 P124Q	Melanoma	VTX-11e Sensitive: D – Preclinical VTX-11e Sensitive : D	VTX-11e Sensitive: D – Preclinical VTX-11e Sensitive : D